The causes and pathogenesis of recurrent polychondritis are not yet clear, so there are no clear and effective prevention methods. However, we can start with the basics, such as exercising more, improving the body’s immunity, cultivating good habits, and maintaining cleanliness. How should I treat recurrent polychondritis if I have it? Mild polychondritis, chondritis limited to the joints, nose or ears, can be treated with non-steroidal anti-inflammatory drugs. More severe forms of polychondritis, such as sclerositis, uveitis and those presenting with systemic symptoms, must begin glucocorticoid therapy with prednisone 30-60 mg/d (or equivalent amounts of other agents) and immunosuppressive agents such as azathioprine or cyclophosphamide. As soon as efficacy occurs, the glucocorticoid dose should be gradually reduced until it is discontinued. Cyclosporine has been used in refractory cases with good results. One patient with renal involvement was treated with monthly intravenous cyclophosphamide shocks for 6 months, and renal function improved. Response to the combination of prednisone plus dapsone and cyclophosphamide has been variable. Acute airway obstruction may require tracheotomy and, if necessary, tracheal dilation. Severe cardiac valve involvement or large angiomas are indications for surgical intervention. Early diagnosis and prompt treatment of patients with RP have the potential to prolong patient survival and achieve a better outcome. The choice of treatment is mainly related to the severity of symptoms and the extent of organ involvement, but there is no uniform treatment plan for everyone. Traditional treatment includes aspirin or other non-steroidal anti-inflammatory drugs, tranylcypromine, and hormones. Barrancoc first treated RP with aminophenazone and received good results. It is believed that aminophenazone inhibits complement activation and lymphocyte transformation in vivo, and also inhibits degenerative changes in cartilage involving lysozyme. The average dose of aminophenazone is 75 mg/d, with a dose range of 25-200 mg/d. The dose is tried in small doses at the beginning, and then gradually increased, and because of the accumulative effect, the dose needs to be stopped for 1 day after 6 days of administration for about 6 months. The main side effects of aminophenazone are drowsiness, hemolytic anemia, drug-related hepatitis, nausea and white blood cell drop. Glucocorticoids and immunosuppressants are to be chosen for patients with moderate to severe cases. Glucocorticoids cannot change the natural disease process of RP, but they can inhibit the acute attack of lesions and reduce the frequency and severity of recurrence. Prednisone is started at 30-60mg/d. In cases of severe acute attacks, such as when the larynx, trachea and bronchi, eyes and inner ear are involved, the dose of prednisone can be 80-200mg/d. After the clinical symptoms improve, the dose can be gradually reduced to 5-20mg/d. The maintenance period of the drug is 3 weeks to 6 years, with an average of 4 months, and a few need long-term continuous medication. In cases where hormone and aminophene therapy is ineffective, or in severe cases, including sclerositis, tracheobronchial chondritis, glomerulonephritis, or heart valve involvement, immunosuppressive agents such as methotrexate, cyclophosphamide, azathioprine, and mercaptopurine should be added. In cases where these treatments have failed, remission has been reported with cyclosporin A (cyclosporin). Other treatments Surgery: In patients with severe epiglottis or subepiglottis obstruction resulting in severe inspiratory distress, tracheotomy and fistula should be performed immediately, even with appropriate ventilation, to obtain further drug therapy. Tracheal intubation is generally not chosen because it can cause sudden death by airway occlusion, and if unavoidable, a thinner intubation should be chosen. Surgical resection is feasible for limited tracheal stenosis due to chondromalacia, but does not significantly improve the prognosis. In cases of heart valve lesions or refractory heart failure due to valvular insufficiency, valve repair or valve replacement is an option. Aortic aneurysms can also be surgically removed. Metal stents: For multiple or more extensive tracheal or bronchial stenoses, metal stents can be placed under fibrinoscopy or X-ray guidance, which can significantly relieve whistling difficulties. Self-expanding metal stents have certain advantages, including easy placement, visible on X-ray, dynamic dilation, ventilation even when the bronchial opening is covered by the stent, placement even during mechanical ventilation, the bronchial epithelium will cover the stent after several weeks while preserving mucosal ciliary function, minimal displacement, and no interference with tracheal intubation. The main complications are cough, hemoptysis, mucus plug, pneumothorax, granuloma formation, and ulceration. Others: For diffuse small airway involvement, transnasal continuous positive endotracheal pressure (CPAP) has been reported to relieve symptoms, to gradually adjust the level of positive end-whistle pressure, which has been reported to be 10 cm H20. For RP combined with vasculitis, connective tissue disease, hematologic disease, etc., treatment of their comorbidities is the main focus. Recurrent polychondritis can be mild or severe, so patients should be treated rationally, not overly stressed, and treatment of the disease requires a pleasant and relaxed state of mind. After healing, patients can continue to maintain good habits, adhere to physical exercise, and face problems with a positive and optimistic attitude, because this can prevent the disease from recurring or other germs.